Filing Flows › Kymera Therapeutics (KYMR) › Q1 2026
Kymera Therapeutics (KYMR) Q1 2026 earnings results (first quarter 2026)
10-Q filed Apr 30, 2026
Kymera Therapeutics (KYMR) reported revenue of $34.4M for the first quarter 2026 (Q1 2026), +55% from a year earlier and up 12-fold from the quarter before. Operating margin was -244.9%, net loss $69.2M (201.5% of revenue).
Kymera Therapeutics, Q1 2026: revenue $34.4M (+56% year over year), operating margin -244.9%, net loss $69.2M, operating cash flow −$88.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $34.4M | 12× | +55% |
| Operating profit | −$84.2M | — | — |
| Net earnings | −$69.2M | — | — |
| Operating cash flow | −$88.8M | — | — |
What changed
Revenue was $34.4M in Q1 2026, up 55% year over year and up 1097% from the previous quarter.
Operating costs exceeded revenue by $84.2M, an operating margin of -244.9%. Total costs grew 23% against revenue growth of 55%. The quarter ended with a net loss of $69.2M, narrower than the previous quarter's $87.0M loss. Non-operating items added $14.9M, -22% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$88.8M. Non-cash charges added back $2.0M of depreciation and amortization and $16.0M of share-based compensation. Working capital and other items used $37.6M. Capital expenditures of $434K exceeded it, leaving free cash flow of −$89.3M.
Questions
What was Kymera Therapeutics' revenue in the first quarter 2026?
Kymera Therapeutics (KYMR) reported revenue of $34.4M for the first quarter 2026 (Q1 2026), +55% from a year earlier and up 12-fold from the quarter before.
Was Kymera Therapeutics profitable in the first quarter 2026?
Operating loss was $84.2M (-244.9% of revenue) and net loss $69.2M.